PTU - Polskie Towarzystwo Urologiczne
list of articles:

Epidemiology of prostate cancer: changes observed in Poland in 1991-2000
Article published in Urologia Polska 2005/58/1.

authors

Jakub Dobruch 1, Andrzej Borówka 1, Artur A. Antoniewicz 1, Piotr Chłosta 2
1 Klinika Urologii Centrum Medycznego Kształcenia Podyplomowego, I Zespół Dydaktyki Urologicznej - Oddział Urologii Międzyleskiego Szpitala Specjalistycznego w Warszawie
Kierownik kliniki i ordynator oddziału: prof. dr hab. Andrzej Borówka
2 Dział Urologii Świętokrzyskiego Centrum Onkologii w Kielcach
Kierownik działu: dr med. Stefan Olszewski

keywords

prostate, prostate cancer, incidence, mortality

summary

introduction and aim of the study
Prostate cancer (PCa - prostatic carcinoma) is one of the most frequently diagnosed cancers and the leading tumor-related cause of death in men worldwide. The aim of the study is to analyze the epidemiological data concerning prostate cancer in Poland and to compare them with respective data in other countries.
material and methods
The data published in Poland, in PubMed and in MEDLINE were analyzed. Only standardized parameters (ASRs - age-adjusted standardized rates) were considered. Prostate cancer incidence and mortality were reviewed.
results
Prostate cancer incidence in Poland gradually increased from 12.2 in 1991 to 18.7 in 2000 (53%). The distribution of prostate cancer as far as the incidence is concerned rose from 5.3% to 8.1%. Prostate cancer-specific mortality increased gradually from 10.1 in 1991 to 12.6 in 2000 (26%). The distribution of prostate cancer as far as the tumor-related mortality is concerned rose from 5.1 in 1991 to 6.6 in 2000.
conclusions
Prostate cancer incidence and mortality have been rising gradually in Poland during the recent years. Improved cancer registration, widespread PSA evaluation, progress in biopsy techniques, and probably increased number of transurethral resections and changes in lifestyle could be the reasons.

references

  1. Wojtyniak B, Goryński P, Seroka W: Stan zdrowia ludności Polski na podstawie danych o umieralności, w: "Sytuacja zdrowotna ludności Polski"; Wojtyniak B, Goryński P (red); Państwowy Zakład Higieny; Warszawa;
  2. -55.
  3. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 2000 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie; w: Krajowy Rejestr Nowotworów; Warszawa 2003,
  4. -105.
  5. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37 (suppl 8); 4-66.
  6. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 1991 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie; w: Krajowy Rejestr Nowotworów; Warszawa 1994, 25-105.
  7. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 1992 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie; w: Krajowy Rejestr Nowotworów; Warszawa 1995, 25-105.
  8. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 1993 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie; w: Krajowy Rejestr Nowotworów; Warszawa 1996,
  9. -105.
  10. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 1996 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie; w: Krajowy Rejestr Nowotworów; Warszawa 1999,
  11. -105.
  12. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 1997 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie; w: Krajowy Rejestr Nowotworów; Warszawa 2000,
  13. -105.
  14. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 1998 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie; w: Krajowy Rejestr Nowotworów; Warszawa 2001,
  15. -105.
  16. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 1999 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie; w: Krajowy Rejestr Nowotworów; Warszawa 2002,
  17. -105.
  18. Potosky AL, Miller BA, Albertsen PC, Kramer BS: The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273; 548-552.
  19. Brawley OW: Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 1997; 80; 1857-1863.
  20. Quinn M, Babb P: Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. Br J Urol Int 2002; 90; 162-174.
  21. Stanford JL, Damber JE, Fair WR et al: Epidemiology of prostate cancer. w: Murphy G, Khoury S, Partin A, Denis L (red) Prostate cancer. Health Publication Ltd, 2000, str. 21-56.
  22. Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW: Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 1990; 82; 1624-1628.
  23. Howe HL, Wingo PA, Hun MJ et al: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93; 824-842.
  24. Merrill RM, Stephenson RA: Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J Urol 2000; 163; 503-510.
  25. Bartsch G, Horninger W, Klocker H et al: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urol 2001; 58; 417-424.
  26. Labrie F, Candas B, Dupont A et al: Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomised controlled trial. Prostate 1999; 38; 83-91.
  27. Mercer SL, Goel V, Levy IG, Ashbury FD, Iversen DC, Iscoe NA: Prostate cancer screening in the midst of controversy: Canadian men´s knowledge, beliefs, utilization, and future intentions. Can J Public Health 1997; 88; 327-332.
  28. Chamberlain J, Melia J, Moss S, Brown J: The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1997; 1; 1-53.
  29. Grosclaude P, Menegoz F, Schaffer P et al: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality gures in France from 1982 to 1990. Prog Urol 1997; 7; 647-654.
  30. Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW: Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in Southeastern Netherlands 1971-1995. Eur J Cancer 1998; 34; 705-709.
  31. Auvinen A, Alexander FE, de Koning HJ, Miller AB: Should we start population screening for prostate cancer? Randomised trials are still needed. Int J Cancer 2002; 97; 377-378.
  32. Oliver SE, Gunnell D, Donovan JL: Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355; 1788-1789.
  33. Slevin TJ, Donelly N, Clarkson JP, English DR, Ward JE: Prostate cancer testing: behaviour, motivation and attitudes among western Australian men. Med J Aust 1999; 171; 185-188.
  34. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ: Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325; 740-745.
  35. Key T: Risk factors for prostate cancer. Cancer Surv 1995; 23; 63-77.
  36. Grőneberg H, Damber L, Damber JE: Total food consumption and body mass index in relation to prostate cancer risk: a case-control study in Sweden with prospectively collected exposure data. J Urol 1996; 155; 969-974.
  37. Morton MS, Turkes A, Denis L, Griffiths K: Czy czynniki dietetyczne wywierają wpływ na choroby gruczołu krokowego. Br J Urol Int wersja polska 1999; 5; 5-10.

correspondence

Jakub Dobruch
Międzyleski Szpital Specjalistyczny
ul. Bursztynowa 2
04-749 Warszawa
tel. 0 503 072 230